Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 645-654

  Leskela S ^a   Honrado, E ^a   Montero Conde, C ^a   Landa, I ^a   Cascon A ^a   Leton R ^a   Talavera, P ^b   Cozar J M ^b   Concha, A ^b   Robledo, M ^a   Rodriguez Antona C ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A43; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CELL; CELL GROWTH; CONTROLLED STUDY; CYP3A GENE; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; MALE; METABOLISM; MICROSOME; NUCLEOTIDE SEQUENCE; PROSTATE; PROSTATE CANCER; PROSTATE CELL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; CARCINOMA; CYTOCHROME P-450 ENZYME SYSTEM; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 35948981637     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0078     Document Type: Article

References (47)

1. Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK & Everson RB 2006 Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urologic Oncology 24 21-27.
2. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P et al. 2002 Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. Journal of Biolgical Chemistry 277 24280-24288.
3. Domanski TL, Finta C, Halpert JR & Zaphiropoulos PG 2001 cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Molecular Pharmacology 59 386-392.
4. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews Cancer 1 34-45.
5. Finnstrom N, Bjelfman C, Soderstrom TG, Smith G, Egevad L, Norlen BJ, Wolf CR & Rane A 2001 Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. European Jouranl of Clinical Investigation 31 880-886.
6. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R et al. 2001 The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11 773-779.
7. Kamdem LK, Meineke I, Koch I, Zanger UM, Brockmoller J & Wojnowski L 2004 Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn-Schmiedeberg's Archives of Pharmacology 370 71-77.
8. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U et al. 2002 Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 30 1108-1114.
9. Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE & Navis G 2005 The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenetics and Genomics 15 831-837.
10. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD et al. 2001 Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 27 383-391.
11. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW & Goldstein JA 2003 Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13 461-472.
12. Li AP, Kaminski DL & Rasmussen A 1995 Substrates of human hepatic cytochrome P450 3A4. Toxicology 104 1-8.
13. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG & Thummel KE 2002 Co-regulation of CYP3 A4 and CYP3 A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 62 162-172.
14. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L & van den Engh G 1997 Cell-cell interaction in prostate gene regulation and cytodifferentiation. PNAS 94 10705-10710.
15. Loukola A, Chadha M, Penn SG, Rank D, Conti DV, Thompson D, Cicek M, Love B, Bivolarevic V, Yang Q et al. 2004 Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. European Journal of Human Genetics 12 321-332.
16. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE & Reichardt JK 1997 A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Research 57 1020-1022.
17. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE & Reichardt JK 1999 Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354 975-978.
18. Masai M, Sumiya H, Akimoto S, Yatani R, Chang CS, Liao SS & Shimazaki J 1990 Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17 293-300.
19. McNeal JE, Price HM, Redwine EA, Freiha FS & Stamey TA 1988a Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. Journal of Urology 139 61-65.
20. McNeal JE, Redwine EA, Freiha FS & Stamey TA 1988b Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. American Journal of Surgical Pathology 12 897-906.
21. McNeal JE 1969 Origin and development of carcinoma in the prostate. Cancer 23 24-34.
22. McNeal JE 1978 Origin and evolution of benign prostatic enlargement. Investigative Urology 15 340-345.
23. Miller KK, Cai J, Ripp SL, Pierce WM Jr, Rushmore TH & Prough RA 2004 Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metabolism and Disposition 32 305-313.
24. Moilanen AM, Hakkola J, Vaarala MH, Kauppila S, Hirvikoski P, Vuoristo JT, Edwards RJ & Paavonen TK 2007 Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis 28 916-921.
25. Murray GI, Pritchard S, Mel vin WT & Burke MD 1995a Cytochrome P450 CYP3A5 in the human anterior pituitary gland. FEBS Letters 364 79-82.
26. Murray GI, Taylor VE, McKay JA, Weaver RJ, Ewen SW, Melvin WT & Burke MD 1995b The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. Journal of Pathology 177 147-152.
27. Novelli G, Margiotti K, Chiocca AM, Spera E, Micali F & Reichardt JK 2004 Pharmacogenetics of human androgens and prostate cancer-an update. Pharmacogenomics 5 283-294.
28. Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M & Kitada M 1998 Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochimica et Biophysic Acta 1380 297-304.
29. Di Paolo OA, Teitel CH, Nowell S, Coles BF & Kadlubar FF 2005 Expression of cytochromes P450 and glutathione S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-, PAPS- and ATP-dependent pathways. International Journal of Cancer 117 8-13.
30. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G & Witte JS 1999 Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiology, Biomarkers & Prevention 8 901-905.
31. Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH, Dossett N, Lang N, Kadlubar FF, Ambrosone CB et al. 2006 Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiology, Biomarkers & Prevention 15 1473-1478.
32. Parnes HL, Thompson IM & Ford LG 2005 Prevention of hormone-related cancers: prostate cancer. Journal of Clinical Oncology 23 368-377.
33. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G & Witte JS 2003 CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 12 928-932.
34. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ & Malkowicz SB 1998 Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Journal of National Cancer Institute 90 1225-1229.
35. Rodriguez-Antona C & Ingelman-Sundberg M 2006 Cytochrome P450 pharmacogenetics and cancer. Oncogene 25 1679-1691.
36. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L & Ingelman-Sundberg M 2005 Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochemical and Biophysical Research Communications 338 299-305.
37. Sim SC, Edwards RJ, Boobis AR & Ingelman-Sundberg M 2005 CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenetics and Genomics 15 625-631.
38. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R & Zhang Z 2001 Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. Journal of Urology 166 2171-2177.
39. Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA & Di Rienzo A 2004 CYP3A variation and the evolution of salt-sensitivity variants. American Journal of Human Genetics 75 1059-1069.
40. Thompson EE, Kuttab-Boulos H, Yang L, Roe BA & Di Rienzo A 2006 Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics Journal 6 105-114.
41. Thummel KE & Wilkinson GR 1998 In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 38 389-430.
42. Villers A, Steg A & Boccon-Gibod L 1991 Anatomy of the prostate: review of the different models. European Urology 20 261-268.
43. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M & Oscarson M 2001 Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochemical and Biophysical Research Communications 281 1349-1355.
44. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR & Ingelman-Sundberg M 2003 Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metabolism and Disposition 31 755-761.
45. Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J, Koch I, Klattig J, Zanger U & Brockmoller J 2002 Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Journal of National Cancer Institute 94 630-631.
46. Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ & McLeod HL 2006 Expression of drug pathway proteins is independent of tumour type. Journal of Pathology 209 213-219.
47. Zhenhua L, Tsuchiya N, Narita S, Inoue T, Horikawa Y, Kakinuma H, Kato T, Ogawa O & Habuchi T 2005 CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Letters 225 237-243.